Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug–Bug Interaction?

Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug–Bug Interaction?

Gut microbial metabolism is not only an important source of uremic toxins but may also help to maintain the vitamin K stores of the host. We hypothesized that sevelamer therapy, a commonly used phosphate binder in patients with end-stage kidney disease (ESKD), associates with a disturbed gut microbi...

Full description

Bibliographic Details
Main Authors: Lu Dai, Björn K. Meijers, Bert Bammens, Henriette de Loor, Leon J. Schurgers, Abdul Rashid Qureshi, Peter Stenvinkel, Pieter Evenepoel
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Toxins
Subjects:
uremic toxins
sevelamer
microbial metabolism
vitamin K
end-stage kidney disease
Online Access:https://www.mdpi.com/2072-6651/12/6/351

Internet

https://www.mdpi.com/2072-6651/12/6/351

Similar Items